HVB MINI FUTURE BULL - ASTRAZENECA | Market Closed - Bid/Ask 19:39:36 26/06/2024 BST | After market 20:02:01 | |||
| 6.91 EUR | -0.29% |
|
6.92 | +0.14% |
| Current month | +5.96% | ||
| 1 month | +3.90% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 26/06/24 | 6.91 | -0.29% |
| 25/06/24 | 6.93 | +1.46% |
| 24/06/24 | 6.83 | -0.58% |
| 21/06/24 | 6.87 | +1.48% |
| 20/06/24 | 6.77 | +0.59% |
Delayed Quote Börse Stuttgart
Last update June 26, 2024 at 07:39 pm
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HR5TXY |
| ISIN | DE000HR5TXY2 |
| Date issued | 25/02/2021 |
| Strike | 6,670 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.36 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.11 € |
|---|---|
| Lowest since issue | 1.01 € |
| Spread | 0.04 € |
| Spread % | 0.58% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
159
USD
Average target price
174.4
USD
Spread / Average Target
+9.66%
- Stock Market
- Certificates
- Certificat
